Castle Biosciences (NASDAQ:CSTL) Sees Large Volume Increase After Earnings Beat

Castle Biosciences, Inc. (NASDAQ:CSTL) shares saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings. Approximately 213,029 shares were traded during trading, a decline of 45% from the previous session’s volume of 388,535 shares.The stock last traded at $28.3940 and had previously closed at $26.79.

The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.37. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The business had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.24 million.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Results exceeded expectations: Castle reported adjusted loss per share of $0.07, substantially better than the $0.41–$0.44 loss analysts expected. Revenue reached approximately $103.5 million, up 20.1% year over year and well above consensus estimates near $86–$88 million. Castle Biosciences Reports Second Quarter 2026 Results
• Positive Sentiment: 2026 outlook raised: Management now expects full-year revenue of $365 million to $375 million, above the approximately $353.2 million analyst consensus. The higher outlook signals continued demand for Castle’s cancer diagnostic tests. Castle Biosciences Lifts 2026 Outlook After Q2 Growth
• Positive Sentiment: Improving operating performance and liquidity: Gross profit increased 16.5% to $79.8 million, while the operating loss narrowed to $3.1 million. Castle generated $15.2 million in operating cash flow and ended the quarter with $62.1 million in cash, supporting continued investment without significant balance-sheet leverage. Castle Biosciences Stock Rises on Q2 2026 Earnings
• Neutral Sentiment: The company remains unprofitable, reporting a net loss of about $2.1 million and an adjusted loss per share, although the loss was considerably smaller than expected. Management did not provide a specific EPS outlook in the available guidance update. Castle Biosciences Q2 2026 Earnings Call Transcript
• Negative Sentiment: Insider trading data shows continued selling, including CEO Derek Maetzold’s recent sale of 9,836 shares under a pre-arranged Rule 10b5-1 plan. While such sales are scheduled and do not necessarily indicate a change in business prospects, the absence of reported insider purchases may weigh on sentiment. Castle Biosciences Insider Transaction Report

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. KeyCorp set a $35.00 target price on Castle Biosciences in a research note on Friday, May 29th. Weiss Ratings lowered Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Roth Capital initiated coverage on Castle Biosciences in a research report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Castle Biosciences has an average rating of “Moderate Buy” and an average price target of $41.43.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 3,622 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $24.16, for a total transaction of $87,507.52. Following the completion of the transaction, the insider owned 11,812 shares in the company, valued at approximately $285,377.92. This represents a 23.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of Castle Biosciences stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total value of $209,670.12. Following the completion of the sale, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at approximately $534,163.08. This trade represents a 28.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 55,025 shares of company stock valued at $1,252,199 over the last three months. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors have recently added to or reduced their stakes in CSTL. Summit Partners Public Asset Management LLC increased its stake in shares of Castle Biosciences by 164.7% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after purchasing an additional 658,725 shares in the last quarter. SummitTX Capital L.P. lifted its stake in shares of Castle Biosciences by 285.0% during the 1st quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock valued at $1,646,000 after buying an additional 49,623 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in shares of Castle Biosciences during the 4th quarter valued at approximately $11,864,000. KBC Group NV purchased a new stake in shares of Castle Biosciences during the 1st quarter valued at approximately $907,000. Finally, SG Americas Securities LLC boosted its holdings in Castle Biosciences by 1,051.8% in the 1st quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock worth $6,012,000 after buying an additional 223,624 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Stock Performance

The company has a market capitalization of $885.06 million, a P/E ratio of -65.20 and a beta of 1.00. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average is $22.61 and its 200 day moving average is $26.51.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.